Search Results

You are looking at 11 - 20 of 420 items for :

  • "single agent" x
Clear All
Full access

Priya Wanchoo, Chris Larrison, Carol Rosenberg, Naomi Ko, Cynthia Cantril, Naomi Moeller, Ruchit Parikh and Ana-Marija Djordjevic

indicated they would treat with either single-agent or combination chemotherapy; 18% said they would treat with exemestane plus everolimus. Abbreviations: ER, estrogen receptor; PR, progesterone receptor. a Inappropriate answer as identified by the

Full access

Robert I. Haddad, William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Judith C. McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann and Miranda Hughes

/doxorubicin regimens were added, which can be used with or without radiation therapy. 31 , 75 , 76 Single-agent cisplatin was deleted, because it is not recommended for patients with advanced/metastatic ATC or those with impaired renal function. In addition, the

Full access

Tanya E. Keenan and Sara M. Tolaney

ICIs are higher in TNBC than in hormone receptor–positive and HER2-positive breast cancers, the single-agent efficacy is still low, with monotherapy response rates ranging from approximately 5% in unselected patients to approximately 23% in treatment

Full access

Suzanne George

are both very solid options,” she maintained. “There is not a clearly superior first-line approach, at least based on these data.” Other Single Agents Versus Combinations As the conventional backbone agent, doxorubicin has been combined with a

Full access

A. Dimitrios Colevas

or metastatic SCCHN over the past 30 years, with the most common design comparing a single agent with combination therapy. However, these randomized comparisons of different drug options are far from exhaustive, and data from uncontrolled clinical

Full access

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory and Deborah A. Freedman-Cass

cancer involves various active drugs, either in combination or as single agents: 5-FU/LV, capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, panitumumab, ziv-aflibercept, and regorafenib. 29 , 30 , 48 - 86 The putative mechanisms of action of

Full access

Donna Trauth and Lori J. Goldstein

1993 ; 20 ( Suppl 3 ): 1 – 15 . 58 Davidson NG . Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience . Semin Oncol 1996 ; 23 ( Suppl 11 ): 6 – 10 . 59 Rowinsky EK McGuire WP

Full access

Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya and George Ansstas

pediatric and adult brain tumors, and several case reports have indicated the potential efficacy of targeted therapy in these patients. To date, these studies have mostly been performed using single-agent BRAF inhibitor therapy in recurrent low-grade gliomas

Full access

Supriya G. Mohile, Allison Magnuson, Chintan Pandya, Carla Velarde, Paul Duberstein, Arti Hurria, Kah Poh Loh, Megan Wells, Sandy Plumb, Nikesha Gilmore, Marie Flannery, Marsha Wittink, Ronald Epstein, Charles E. Heckler, Michelle Janelsins, Karen Mustian, Judith O. Hopkins, Jane Liu, Srihari Peri and William Dale

recommend treatment with first-line chemotherapy (yes/no) (Model A). In cases when chemotherapy was recommended, a second regression was conducted, predicting whether oncologists recommended single-agent chemotherapy or combination chemotherapy (Model B

Full access

Saby George, Roberto Pili, Michael A. Carducci and Jenny J. Kim

). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. 1 Lastly, improved